Design of Phase II Non-inferiority Trials. Read more about Design of Phase II Non-inferiority Trials.
Change-Plane Analysis for Subgroup Detection and Sample Size Calculation. Read more about Change-Plane Analysis for Subgroup Detection and Sample Size Calculation.
Reweighted estimators for additive hazard model with censoring indicators missing at random. Read more about Reweighted estimators for additive hazard model with censoring indicators missing at random.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Read more about Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. Read more about Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy.
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Read more about PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
Embracing rejection: Immunologic trends in brain metastasis. Read more about Embracing rejection: Immunologic trends in brain metastasis.
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Read more about Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp Read more about A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp
